The Phase Iii Lucidity Trial: A Tau Aggregation Inhibitor In Patients With Alzheimers Disease

The Phase III LUCIDITY trial: a tau aggregation inhibitor in patients with Alzheimer’s disease

The promise of tau aggregation inhibitors in dementia

First Phase 3 Clinical Trials Targeting the Tauopathy of Alzheimer’s Disease - Claude Wischik

SENS Research Foundation

Alzheimer Disease: Other Therapies Under Investigation

New hope as Alzheimer’s drug slows memory decline in phase 3 trial

Alzheimer's Research UK

SENS4 - Tau Aggregation Inhibitor Therapy For Neurodegenerative Disorders (1/2)

Clinical Trials And Research: TauRx: 'Hope in the Age of Dementia'

Alzheimer's Disease International

Why Alzheimer’s disease research is focusing on tau

Time saved in Alzheimer’s disease in Phase III trial of donanemab

Disrupting Tau Aggregation: A New Approach to Alzheimer's Therapy

University Hospitals

SENS4 - Tau Aggregation Inhibitor Therapy For Neurodegenerative Disorders (1/2)

Phase III ADMET2 trial of methylphenidate for apathy in Alzheimer's Disease

Structure of tau filament in Alzheimer’s disease

Rejaul Hoq Nayeem

Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action

Experimental Alzheimer's drug shows benefits in phase 3 trial

Uncovering the Reality of End-Stage Alzheimer's: How the Dying Process Unfolds 😶‍🌫

Methylation regulates Tau aggregation and neuronal health in Alzheimer’s disease

AJE Video Bytes

Alzheimer's disease - plaques, tangles, causes, symptoms & pathology

Osmosis from Elsevier

Research Highlight: Toxic tau aggregates determines type of dementia

UT Southwestern Medical Center

Washington University in St. Louis Leads International Alzheimer’s Clinical Trial to Test Tau Drugs

HEC Science & Technology